Search
refractory anemia with excess blasts (RAEB)
Epidemiology:
-> 23% of cases of myelodysplastic syndrome
Pathology:
1) circulating blasts < 5%
2) bone marrow blasts 5-20%
3) < 15% ringed sideroblasts in marrow
4) no Auer rods
Management:
-> prognosis:
a) 11-50% transformation to acute leukemia (AML)
b) survival 7-15 months (mean 9 months)
General
myelodysplastic syndrome (MDS)
References
Harrison's Principles of Internal Medicine, 14th ed.
Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 677-78